Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vick, N. A.
Right arrow Articles by Walsh, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vick, N. A.
Right arrow Articles by Walsh, A.
NEUROLOGY 1989;39:430
© 1989 American Academy of Neurology

Reoperation for malignant astrocytoma

N. A. Vick, MD, I. S. Ciric, MD, T. W. Eller, MD, J. W. Cozzens, MD and A. Walsh, RN

Division of Neurology, Evanston Hospital and Northwestern University Medical School, Evanston, IL. (Dr. Vick and MB. Walsh)
Division of Neurosurgery, Evanston Hospital and Northwestern University Medical School, Evanston, IL. (Drs. Ciric, Eller, and Cozzens)

We evaluated 15 consecutive patients with malignant astrocytomas who were reoperated for functional status and survival. Their Karnovsky Performance Status (KPS) was not changed by surgery. None suffered perioperative death, wound infection, or complications. Patients with glioblastoma maintained KPS unchanged for a mean of 13 weeks (median, 10 weeks); with anaplastic astrocytoma, mean, 37.2 weeks (median, 24 weeks). Life spans were approximately twice that of non-reoperated historical controls. Reoperation for patients with recurrent malignant astrocytoma should be seriously considered when a gross total re-resection can be the goal in a patient whose tumor is in an accessible brain region.

Address correspondence and reprint requests to Dr. Vick, Division of Neurology, Evanston Hospital, 2650 Ridge Avenue, Evanston, IL 60201.

Supported by NIH grant P50 NS20023 and the W. Freeman Memorial Fund.

Received July 19, 1988. Accepted for publication in final form September 26, 1988.




This article has been cited by other articles:


Home page
 Neuro Oncol DukeHome page
D. A. Larson, J. M. Suplica, S. M. Chang, K. R. Lamborn, M. W. McDermott, P. K. Sneed, M. D Prados, W. M. Wara, M. K. Nicholas, and M. S. Berger
Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme
Neuro-oncol, April 1, 2004; 6(2): 119 - 126.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by AAN Enterprises, Inc.